Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.62 |
| ▸ | TLR2 | O60603 | 4/20 | 0.55 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.54 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.54 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.53 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31182653 | 0.91 | BACE1 (0.62) | BACE1VIPR1PTH1RVIPR2 | |
| SCHEMBL30903279 | 0.91 | BACE1 (0.62) | BACE1VIPR1VIPR2KISS1RCRHR1 | |
| SCHEMBL31182757 | 0.90 | VIPR1 (0.64) | BACE1VIPR1VIPR2KISS1R | |
| SCHEMBL29965017 | 0.90 | BACE1 (0.57) | BACE1VIPR1PTH1RVIPR2 | |
| SCHEMBL30512733 | 0.89 | BACE1 (0.63) | BACE1PTH1R | |
| SCHEMBL30176488 | 0.88 | BACE1 (0.62) | BACE1VIPR1VIPR2KISS1R | |
| SCHEMBL29438037 | 0.88 | BACE1 (0.60) | BACE1VIPR1VIPR2 | |
| SCHEMBL30974316 | 0.88 | VIPR1 (0.60) | BACE1VIPR1VIPR2KISS1R | |
| SCHEMBL29679758 | 0.88 | BACE1 (0.60) | BACE1PTH1R | |
| SCHEMBL29679584 | 0.87 | BACE1 (0.53) | BACE1KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629409-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-05-19 | — | — | US | disclosed |
| US-20240226261-A9 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-07-11 | — | — | US | disclosed |
| US-20240131136-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-04-25 | — | — | US | disclosed |
| US-11844828-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-12-19 | — | — | US | disclosed |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-03-02 | — | — | US | disclosed |
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-09-15 | — | — | US | disclosed |
| US-20220152182-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-05-19 | — | — | US | disclosed |
| US-11266731-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | BACE1 3167/4885TLR2 2083/4885VIPR1 814/4885 |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | BACE1 3167/4885TLR2 2083/4885VIPR1 814/4885 |
| US-12629409-B2 | Vaccine | MRPL21, STT3B, CD47 | BACE1 3708/4885TLR2 55/4885VIPR1 3836/4885 |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | CXCL10, CCL2, CCL11 | BACE1 2692/4885TLR2 14/4885VIPR1 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.